Supporting you every step of the way

Novo Nordisk offers programs and tools to support you all along your journey. Product assistance is available to help you get treatment, and there are resources to help you start on or continue treatment. Eligibility requirements apply.


SID
Sid has congenital hemophilia with inhibitors


 



 


 

Get the treatment you deserve

See how Novo Nordisk can help

The costs of having a bleeding disorder can sometimes be overwhelming. Novo Nordisk may be able to help you get treatment.

Find out if you are eligible for:

  • Co-pay assistancea that can help you save up to $12,000 annually on co-pay, deductible, and coinsurance costs, regardless of income
  • Product assistanceb that provides NovoSeven® RT to qualifying applicants at no charge


a
For people who are privately insured.
bFor people who are uninsured or have a gap in their insurance. Patients participating in any government, state, or federally funded medical or prescription benefit programs, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, are not eligible to participate in ASSIST.


 



 


 

Product Assistance Program (PAP)

People with hemophilia A or B with inhibitors, congenital factor VII deficiency, acquired hemophilia, or Glanzmann's thrombasthenia with a decreased or absent response to platelet transfusions may be able to get help with treatment costs through the Novo Nordisk Hemophilia and Rare Bleeding Disorder Product Assistance Program (PAP). You or your loved one may be eligible if you are:

  • Prescribed a Novo Nordisk factor product
  • Currently uninsured and actively seeking product

Download the Product Assistance Program application to start or call 1-844-NOVOSEC (1-844-668-6732) to learn more.


 



 


 

Co-pay Assistance Program

Through the Novo Nordisk Co-pay Assistance Program, eligible patients receive up to $12,000 per year toward their co-pay for Novo Nordisk Hemophilia and Rare Bleeding Disorder products. Click here to see full terms and conditions. You or your loved one may be eligible if you are:

  • Prescribed a Novo Nordisk factor product
  • Currently privately/commercially insured


 



 


 

Watch a video on how to mix a dose

NovoSeven® RT with MixPro® can be prepared in 3 steps: attach, twist, and mix. You will be guided through the process in this video as you watch a dose being mixed. Do not attempt to do an infusion yourself unless you have been taught how by your health care professional or hemophilia treatment center.


 



 


 

Get a NovoSeven® RT Travel Kit

The NovoSeven® RT Travel Kit is designed for people who are on the go. This portable, reusable travel case makes storing supplies easy, at home or on the go. To get a Ready-to-Travel Case, call 1-877-NOVO-777 (1-877-668-6777).


 


NovoSecure™

Get access to support designed for the bleeding disorders community. Visit MyNovoSecure.com or call 1-844-NOVOSEC (1-844-668-6732) to learn more and enroll. Novo Nordisk product usage is not an eligibility requirement of NovoSecure™.


Selected Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for:

  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann's thrombasthenia who have a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Warnings and Precautions

  • NovoSeven® RT should be used with caution if you have an increased risk for blood clots, such as with disseminated intravascular coagulation (DIC), clogged arteries, crush injury, septicemia (an infection in the blood), uncontrolled bleeding after giving birth, history of heart disease, liver disease, limited movement following surgery, in elderly people, in newborns, or if you are taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) with NovoSeven® RT.
  • Allergic reactions, including serious whole body allergic reactions, have been reported with NovoSeven® RT. Tell your healthcare provider if you are allergic to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. If you think you are having an allergic reaction, call your healthcare provider right away. Some signs of allergic reaction may include shortness of breath, rash, itching, redness of the skin, and fainting/dizziness.
  • People with Factor VII deficiency should be monitored by their healthcare provider for antibodies, which can cause NovoSeven® RT to stop working properly.

Side Effects

  • The most common and serious side effects are blood clots.
  • Tell your healthcare provider about any side effects that bother you or do not go away.

Use with Other Drugs

  • Blood clots may occur if NovoSeven® RT is given with Coagulation Factor XIII (13).

Please click here for Prescribing Information and Instructions for Use.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

NovoSeven® RT is a prescription medication. Novo Nordisk provides patient assistance for those who qualify. Please call 1-877-NOVO-777 (1-877-668-6777) to learn more about Novo Nordisk assistance programs.